Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank McCormick

Showing results (241-250 of 303) with videos related to

Pageof 31
Sort By:
Nature|November 2, 2017
Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibitionMatthew J Hangauer, Vasanthi S Viswanathan, Matthew J Ryan, et al.
The Journal of Investigative Dermatology|July 1, 2020
Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3Kα/δ and HDACChi-Heng Wu, Chen-Yen Yang, Linlin Wang, et al.
Cancer Discovery|August 8, 2014
Development of siRNA payloads to target KRAS-mutant cancerTina L Yuan, Christof Fellmann, Chih-Shia Lee, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 11, 2019
Second harmonic generation detection of Ras conformational changes and discovery of a small molecule binderElizabeth Donohue, Sina Khorsand, Gabriel Mercado, et al.
Nature Communications|January 10, 2026
Structure of SHOC2-KRAS-PP1C complex reveals RAS isoform-specific determinants and insights into targeting complex assembly by RAS inhibitorsDaniel A Bonsor, Lorenzo I Finci, Jacob R Potter, et al.
Cancer Cell|October 8, 2013
Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic targetLuika A Timmerman, Thomas Holton, Mariia Yuneva, et al.
Nature Communications|February 20, 2021
KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activationTimothy H Tran, Albert H Chan, Lucy C Young, et al.
Biorxiv : the Preprint Server for Biology|April 16, 2025
Selective targeting of oncogenic KRAS G12D using peptide nucleic acid oligomers attached to cell-penetrating peptidesJayati Mondal, Dennis Lam, Mary E Gerritsen, et al.
Science Advances|July 14, 2023
RAS-dependent RAF-MAPK hyperactivation by pathogenic RIT1 is a therapeutic target in Noonan syndrome-associated cardiac hypertrophyAntonio Cuevas-Navarro, Morgan Wagner, Richard Van, et al.
Methods in Molecular Biology (Clifton, N.J.)|July 25, 2024
Determining KRAS4B-Targeting Compound Specificity by Top-Down Mass SpectrometryRobert A D'Ippolito, Grace M Scheidemantle, Dana Rabara, et al.
Pageof 31

Showing results (241-250 of 303) with videos related to

Sort By:
Pageof 31
Nature|November 2, 2017
Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibitionMatthew J Hangauer, Vasanthi S Viswanathan, Matthew J Ryan, et al.
The Journal of Investigative Dermatology|July 1, 2020
Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3Kα/δ and HDACChi-Heng Wu, Chen-Yen Yang, Linlin Wang, et al.
Cancer Discovery|August 8, 2014
Development of siRNA payloads to target KRAS-mutant cancerTina L Yuan, Christof Fellmann, Chih-Shia Lee, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 11, 2019
Second harmonic generation detection of Ras conformational changes and discovery of a small molecule binderElizabeth Donohue, Sina Khorsand, Gabriel Mercado, et al.
Nature Communications|January 10, 2026
Structure of SHOC2-KRAS-PP1C complex reveals RAS isoform-specific determinants and insights into targeting complex assembly by RAS inhibitorsDaniel A Bonsor, Lorenzo I Finci, Jacob R Potter, et al.
Cancer Cell|October 8, 2013
Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic targetLuika A Timmerman, Thomas Holton, Mariia Yuneva, et al.
Nature Communications|February 20, 2021
KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activationTimothy H Tran, Albert H Chan, Lucy C Young, et al.
Biorxiv : the Preprint Server for Biology|April 16, 2025
Selective targeting of oncogenic KRAS G12D using peptide nucleic acid oligomers attached to cell-penetrating peptidesJayati Mondal, Dennis Lam, Mary E Gerritsen, et al.
Science Advances|July 14, 2023
RAS-dependent RAF-MAPK hyperactivation by pathogenic RIT1 is a therapeutic target in Noonan syndrome-associated cardiac hypertrophyAntonio Cuevas-Navarro, Morgan Wagner, Richard Van, et al.
Methods in Molecular Biology (Clifton, N.J.)|July 25, 2024
Determining KRAS4B-Targeting Compound Specificity by Top-Down Mass SpectrometryRobert A D'Ippolito, Grace M Scheidemantle, Dana Rabara, et al.
Pageof 31